



Dr. Nadine Shehata – Alloimmunization Secondary to Pregnancy and Transfusion in Women of Child bearing Age

Alloimmunization (the development of an antibody to a foreign red cell antigen) occurs in women who are exposed to foreign paternal antigens during pregnancy or to foreign red cell antigens from red cell transfusion as alloantibody development occurs when an individual does not have the antigen of which she is exposed. If the alloantibody is an IgG alloantibody, it can traverse the placenta (IgM antibodies do not traverse the placenta), bind to the cognate antigen on the red cells of the fetus causing destruction of red cells and thus fetal anemia (hemolytic disease of the fetus (HDF)). Anemia can extend to the neonatal period (hemolytic disease of the newborn (HDN)).

The risk of development of an alloantibody is not only dependent on exposure but also on the immunogenicity of the red cell antigen, the volume of red cell antigen exposed (higher volumes of red cell antigen exposure is associated with higher the risk of developing alloantibodies during pregnancy), the gestational age when the antigen develops in utero (earlier in gestation is associated with increases the risk of developing alloantibodies during pregnancy) and the ability for the mother to develop a cytotoxic antibody.

Because of these factors, not all mothers develop an alloantibody that is capable of causing HDFN. Once a woman develops an alloantibody however, there is a risk of severe HDFN e.g. fetal anemia although some women do not have HDFN. The D, K and c antigen are associated with more severe HDFN.

Preventing alloantibody development prevents the risk of HDFN particularly severe disease. Prevention of alloimmunization is achieved by reducing exposure to paternal antigens and/or red cell antigens via red cell transfusion. The only paternal red cell antigen exposure that can be prevented/reduced is exposure to paternal D antigen by administering Rh immune globulin (RhIG) to the mother prophylactically or when there is fetal maternal hemorrhage (entry of fetal blood into the maternal circulation) as occurs during normal pregnancy or risk of fetal maternal hemorrhage (as occurs with trauma during pregnancy).

RhIG is a plasma derived product from donors with high anti-D antibodies. It is administered prophylactically at 28 weeks gestation to D negative mothers and after delivery if the neonate is D+. The prophylactic dose at 28 weeks gestation administered to a D negative mother assumes the father is D+. RhIG is also given within 72 hours of a sensitizing event (from fetal maternal hemorrhage) but may be given up 10 days after such an event.

Reduction of exposure of red cell antigens from red cell transfusion is achieved by red cell transfusion avoidance unless necessary (e.g. bleeding or symptomatic anemia) or if red cell transfusion is required, by administering K antigen negative red blood cells (which can be requested from the blood bank) to women of child bearing age to prevent alloimmunization to the K antigen.

Red blood cell transfusion is often prescribed according to hemoglobin concentrations. During pregnancy the hemoglobin concentration decreases because of hemodilution (increased blood volume relative to red cell mass). As such, hemoglobin concentrations decrease in pregnancy to a maximum of approximately 15g/L by the third trimester. As there are no trials of hemoglobin transfusion thresholds for red cell transfusion during pregnancy, transfusion is administered with anemia in pregnancy if the mother is symptomatic or bleeding or if the fetus is symptomatic (e.g. fetal tachycardia). Nonetheless the most common cause of anemia in pregnancy is iron deficiency so that ensuring mothers are iron replete by using prenatal vitamins and checking CBCs at the end of the first trimester to ensure a mother is not becoming anemic potentially results in a reduction of anemia and need for transfusion. Iron deficiency anemia can be treated with iron salts during the entire pregnancy and iv iron (iron sucrose) in the second and third trimester.



Dr. Jacob Pendergrast, Sickle Cell Disease

QUESTIONS/COMMENTS?

<ul style="list-style-type: none">▶ PRINCIPLES<ul style="list-style-type: none">▶ Decr HgbS%, generally more important than increasing total Hgb▶ Benefit only with high-shear vasculature▶ Ceiling of Hgb ~100 g/L	<ul style="list-style-type: none">▶ WEAK EVIDENCE WITH PREGNANCY<ul style="list-style-type: none">▶ Available evidence suggests more benefit for mom than developing fetus▶ There may be exceptions (eg., signs of placental insufficiency, prev IUGR)
<ul style="list-style-type: none">▶ CAUTION WITH SEVERE ANEMIA<ul style="list-style-type: none">▶ Aplastic crisis: <i>volume overload</i>▶ Sequestration: <i>autotransfusion</i>▶ Hyperhemolysis: <i>worsening anemia</i>	<ul style="list-style-type: none">▶ GOOD EVIDENCE FOR STROKE PREVENTION<ul style="list-style-type: none">▶ Transfusion indicated for all children with high-risk dopplers and history of stroke▶ Smaller value for children with SCIs▶ Limited evidence in adults; look for other causes, caution with hemorrhagic stroke
<ul style="list-style-type: none">▶ NUANCED APPROACH FOR SURGERY<ul style="list-style-type: none">▶ Usually not needed for low-risk patient with low risk procedure▶ Indicated for everyone else, top-up vs exchange depends on comorbidity, procedure risk, baseline hemoglobin	<ul style="list-style-type: none">▶ THERAPEUTIC TRANSFUSION IF ACUTE ORGAN COMPROMISE<ul style="list-style-type: none">▶ Limited evidence, but consensus supports transfusion for acute stroke, acute chest syndrome, sickle hepatopathy▶ Other situations: "if all else fails"
<ul style="list-style-type: none">▶ SELECTION OF RBCs MUST BE DONE WITH CARE!<ul style="list-style-type: none">▶ Tell your blood bank early that your patient has sickle cell, provide detailed transfusion history	